Thomsen–Friedenreich antigen

Thomsen–Friedenreich antigen (Galβ1-3GalNAcα1) is a disaccharide.[1] It is usually present on cell surfaces in a cryptic form covered by [2] N-Acetylneuraminic acid moieties, and is released into circulation in many different cancers.

Abstract

The Thomsen–Friedenreich antigen (Gal-GalNAc) represents a tumor-associated molecule, which is assumed to be one of the few chemically well-defined antigens with a proven association with malignancy. In order to analyze the role of the carbohydrate structure Gal-GalNAc for gastrointestinal tumors, Balb/c mice with MCF-7 breast tumor cells were immunized, together with synthetic Gal-GalNAc linked to a BSA carrier. One monoclonal antibody (82-A6) was established that recognizes the Thomsen–Friedenreich antigen according to the biochemical and serological analysis presented here.

In contrast to studies performed in the past, immunohistochemical results using the antibody 82-A6 did not exhibit a reactivity clearly restricted to tumors. Preliminary biochemical analysis revealed that the T-determinant is detectable in the high-molecular weight range (about 1000 kD), suggesting that the Gal-GalNAc epitope is found on mucin-like glycoproteins. Tumor restriction of the Thomsen–Friedenreich antigen may therefore be determined either by the protein backbone or by the beta-glycosidic linkage of the carbohydrate structure to the protein.

References

  1. ↑ Yu, Lu-Gang (2007). "The oncofetal Thomsen–Friedenreich carbohydrate antigen in cancer progression". Glycoconjugate Journal. 24 (8): 411–20. doi:10.1007/s10719-007-9034-3. PMID 17457671.
  2. ↑ http://pedsccm.org/RARE/HUS.html%5Bunreliable+medical+source?%5D
  • Dippold, W.; Steinborn, A.; Büschenfelde, K. H. M. z. (1990). "The Role of the Thomsen-Friedenreich Antigen As a Tumor-Associated Molecule". Environmental Health Perspectives. 88: 255–7. doi:10.2307/3431086. JSTOR 3431086. PMC 1568008. PMID 2272320.
  • King, MJ; Holburn, AM (1979). "Radioassays of blood group M, N and T (Thomsen-Friedenreich) antigens". Immunology. 38 (1): 129–36. PMC 1457886. PMID 511213.
  • Singh, R.; Campbell, BJ; Yu, LG; Fernig, DG; Milton, JD; Goodlad, RA; Fitzgerald, AJ; Rhodes, JM (2001). "Cell surface-expressed Thomsen-Friedenreich antigen in colon cancer is predominantly carried on high molecular weight splice variants of CD44". Glycobiology. 11 (7): 587–92. doi:10.1093/glycob/11.7.587. PMID 11447138.
  • Wolf, Michael F.; Koerner, Ulrike; Schumacher, Kurt (1986). "Specificity of reagents directed to the Thomsen-Friedenreich antigen and their capacity to bind to the surface of human carcinoma cell lines". Cancer Research. 46 (4 Pt 1): 1779–82. PMID 2418954.
  • Uhlenbruck, G. (1981). "The Thomsen-Friedenreich (TF) Receptor: An Old History with New Mystery". Immunological Investigations. 10 (3): 251–64. doi:10.3109/08820138109093459. PMID 7037612.
  • Dippold, W; Steinborn, A; Meyer; Büschenfelde, KH (August 1990). "The role of the Thomsen-Friedenreich antigen as a tumor-associated molecule". Environ. Health Perspect. 88: 255–7. doi:10.2307/3431086. JSTOR 3431086. PMC 1568008. PMID 2272320.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.